2.50
Hdl Handle:
http://hdl.handle.net/2336/76378
Title:
MYC amplification and TERT expression in breast tumor progression
Authors:
Bodvarsdottir, Sigridur K; Steinarsdottir, Margret; Hilmarsdottir, Holmfridur; Jonasson, Jon G; Eyfjord, Jorunn E
Citation:
Cancer Genet. Cytogenet. 2007, 176(2):93-9
Issue Date:
15-Jul-2007
Abstract:
The complex roles of genomic instability, MYC oncogene amplification, activation of telomerase, and p53 function still remain to be fully described in breast tumors. MYC stimulates the telomerase catalytic subunit, TERT, which interacts with p53. Oncogene MYC amplification analysis was performed on 27 paraffin-embedded breast tumor samples by fluorescence in situ hybridization, selected on the basis of chromosomal instability. TERT immunostaining was performed on a larger group of breast tumor sections. All tumor samples were analyzed for TP53 mutation, genomic index, S-phase fraction, and pathological stages. Amplification of MYC was detected in 16 of 27 tumors (59%) and found to be associated with TNM stages I and II (P = 0.018), genomic index > 1.5 (P = 0.033), and S-phase fraction > 5% (P = 0.020). No association was found between MYC amplification and TERT immunostaining or TP53 mutations. Analysis of TERT in 103 primary breast tumors showed > 50% nuclei immunostaining in 58% of cases. High TERT immunostaining associated with genomic index > 1.5 (P = 0.017), high S-phase fraction (P = 0.056), and TP53 mutations (P = 0.030). No association was found between TERT staining and TNM stages. This study supports early involvement of MYC amplification in breast tumor progression. Both MYC amplification and TERT expression appear to be associated with high genomic instability and proliferation. TERT association with TP53 mutations indicates that TERT activity is downregulated by functional p53 protein in breast tumors.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1016/j.cancergencyto.2007.04.002

Full metadata record

DC FieldValue Language
dc.contributor.authorBodvarsdottir, Sigridur K-
dc.contributor.authorSteinarsdottir, Margret-
dc.contributor.authorHilmarsdottir, Holmfridur-
dc.contributor.authorJonasson, Jon G-
dc.contributor.authorEyfjord, Jorunn E-
dc.date.accessioned2009-08-05T14:50:43Z-
dc.date.available2009-08-05T14:50:43Z-
dc.date.issued2007-07-15-
dc.date.submitted2009-08-05-
dc.identifier.citationCancer Genet. Cytogenet. 2007, 176(2):93-9en
dc.identifier.issn1873-4456-
dc.identifier.pmid17656250-
dc.identifier.doi10.1016/j.cancergencyto.2007.04.002-
dc.identifier.urihttp://hdl.handle.net/2336/76378-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe complex roles of genomic instability, MYC oncogene amplification, activation of telomerase, and p53 function still remain to be fully described in breast tumors. MYC stimulates the telomerase catalytic subunit, TERT, which interacts with p53. Oncogene MYC amplification analysis was performed on 27 paraffin-embedded breast tumor samples by fluorescence in situ hybridization, selected on the basis of chromosomal instability. TERT immunostaining was performed on a larger group of breast tumor sections. All tumor samples were analyzed for TP53 mutation, genomic index, S-phase fraction, and pathological stages. Amplification of MYC was detected in 16 of 27 tumors (59%) and found to be associated with TNM stages I and II (P = 0.018), genomic index > 1.5 (P = 0.033), and S-phase fraction > 5% (P = 0.020). No association was found between MYC amplification and TERT immunostaining or TP53 mutations. Analysis of TERT in 103 primary breast tumors showed > 50% nuclei immunostaining in 58% of cases. High TERT immunostaining associated with genomic index > 1.5 (P = 0.017), high S-phase fraction (P = 0.056), and TP53 mutations (P = 0.030). No association was found between TERT staining and TNM stages. This study supports early involvement of MYC amplification in breast tumor progression. Both MYC amplification and TERT expression appear to be associated with high genomic instability and proliferation. TERT association with TP53 mutations indicates that TERT activity is downregulated by functional p53 protein in breast tumors.en
dc.language.isoenen
dc.publisherElsevier/North-Hollanden
dc.relation.urlhttp://dx.doi.org/10.1016/j.cancergencyto.2007.04.002en
dc.subject.meshBreast Neoplasmsen
dc.subject.meshCarcinoma, Ductal, Breasten
dc.subject.meshCell Proliferationen
dc.subject.meshDisease Progressionen
dc.subject.meshGene Amplificationen
dc.subject.meshGenes, mycen
dc.subject.meshGenes, p53en
dc.subject.meshGenomic Instabilityen
dc.subject.meshHumansen
dc.subject.meshKaryotypingen
dc.subject.meshMutationen
dc.subject.meshS Phaseen
dc.subject.meshTelomeraseen
dc.subject.meshTumor Cells, Cultureden
dc.titleMYC amplification and TERT expression in breast tumor progressionen
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, University of Iceland, Vatnsmýrarvegi 16, 101 Reykjavik, Iceland.en
dc.identifier.journalCancer genetics and cytogeneticsen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.